Competing designs for phase I clinical trials: a review
暂无分享,去创建一个
[1] Nancy Flournoy,et al. UP-AND-DOWN DESIGNS II: EXACT TREATMENT MOMENTS , 1995 .
[2] M. Ratain,et al. Perceptions of cancer patients and their physicians involved in phase I trials. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] J B Greenhouse,et al. Bayesian methods for phase I clinical trials. , 1992, Statistics in medicine.
[4] S Chevret,et al. The continual reassessment method in cancer phase I clinical trials: a simulation study. , 1993, Statistics in medicine.
[5] S. Durham,et al. A random walk rule for phase I clinical trials. , 1997, Biometrics.
[6] John O'Quigley,et al. Consistency of continual reassessment method under model misspecification , 1996 .
[7] S. Zacks,et al. Sequential Search of an Optimal Dosage, I , 1973 .
[8] S. Piantadosi,et al. Practical implementation of a modified continual reassessment method for dose-finding trials , 1998, Cancer Chemotherapy and Pharmacology.
[9] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[10] D. Faries,et al. Practical modifications of the continual reassessment method for phase I cancer clinical trials. , 1994, Journal of biopharmaceutical statistics.
[11] David J. Spiegelhalter,et al. Bayesian Approaches to Randomized Trials , 1994, Bayesian Biostatistics.
[12] Jeffrey R. Eisele,et al. A Curve‐Free Method for Phase I Clinical Trials , 2000, Biometrics.
[13] Nancy Flournoy,et al. Random Walks for Quantile Estimation , 1994 .
[14] William F. Rosenberger,et al. Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs , 1997 .
[15] C. Palmer,et al. Ethics and Practice , 1999 .
[16] Y K Cheung,et al. Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.
[17] N L Geller,et al. Design of phase I and II clinical trials in cancer: a statistician's view. , 1984, Cancer investigation.
[18] W F Rosenberger,et al. Ethics and practice: alternative designs for phase III randomized clinical trials. , 1997, Controlled clinical trials.
[19] Ethan Reiner,et al. A stopping rule for the continual reassessment method , 1998 .
[20] B E Storer,et al. Design and analysis of phase I clinical trials. , 1989, Biometrics.
[21] R. Tsutakawa. Selection of Dose Levels for Estimating a Percentage Point of a Logistic Quantal Response Curve , 1980 .
[22] Shelemyahu Zacks,et al. Optimal Bayesian-feasible dose escalation for cancer phase I trials , 1998 .
[23] J O'Quigley,et al. Two-sample continual reassessment method. , 1999, Journal of biopharmaceutical statistics.
[24] S. Chevret,et al. Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. , 1991, Statistics in medicine.
[25] B E Storer,et al. Small-sample confidence sets for the MTD in a phase I clinical trial. , 1993, Biometrics.
[26] Robert K. Tsutakawa,et al. Design of Experiment for Bioassay , 1972 .
[27] J. Whitehead,et al. Bayesian decision procedures with application to dose-finding studies , 1997 .
[28] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[29] William F. Rosenberger,et al. New directions in adaptive designs , 1996 .
[30] Nancy Flournoy,et al. A Clinical Experiment in Bone Marrow Transplantation: Estimating a Percentage Point of a Quantal Response Curve , 1993 .
[31] William F. Rosenberger,et al. Toxicity in sequential dose-response experiments , 1995 .
[32] S. Møller,et al. An extension of the continual reassessment methods using a preliminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses. , 1995, Statistics in medicine.
[33] S Zacks,et al. Cancer phase I clinical trials: efficient dose escalation with overdose control. , 1998, Statistics in medicine.
[34] Douglas G. Simpson,et al. Recursive nonparametric testing for dose-response relaflonships subject to downturns at high doses , 1986 .
[35] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[36] Nancy Flournoy,et al. Dose Finding Using the Biased Coin Up‐and‐Down Design and Isotonic Regression , 2002, Biometrics.
[37] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[38] Alessandra Giovagnoli,et al. Properties of frequency distributions induced by general ‘up-and-down’ methods for estimating quantiles , 1998 .
[39] J O'Quigley,et al. Another look at two phase I clinical trial designs. , 1999, Statistics in medicine.
[40] S. Ruberg,et al. Dose response studies. I. Some design considerations. , 1995, Journal of biopharmaceutical statistics.
[41] S. Piantadosi,et al. Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.
[42] Quentin F. Stout,et al. Flexible Algorithms for Creating and Analyzing Adaptive Sampling Procedures , 1998 .
[43] Ethan Reiner,et al. Operating characteristics of the standard phase I clinical trial design , 1999 .
[44] J Whitehead,et al. Bayesian decision procedures based on logistic regression models for dose-finding studies. , 1998, Journal of biopharmaceutical statistics.
[45] L V Rubinstein,et al. A comparison of two phase I trial designs. , 1994, Statistics in medicine.
[46] A. Watson,et al. Quest: A Bayesian adaptive psychometric method , 1983, Perception & psychophysics.
[47] R. Tsutakawa,et al. Bayesian design for dose-response curves with penalized risk. , 1997, Biometrics.
[48] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[49] J Whitehead,et al. Bayesian decision procedures for dose determining experiments. , 1995, Statistics in medicine.